Novel therapeutics
targeting
diseases of aging

Developing treatments for
complex rare diseases
(NASDAQ: LRMR)

Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

Breakthrough computer-aided
drug design
for transformative medicines

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Applying new insights in
hepcidin biology to
treat hematologic diseases

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Bispecific antibodies
to improve the treatment
of serious diseases

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Targeting regulators of
innate and adaptive immunity
to restore immune homeostasis

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Building
the future of
gene therapy

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

First-in-class RNA therapies
for severe genetic diseases
IPO Jun 2018 (NASDAQ: TBIO)

Disease modifying therapies
for patients with rare
cardiopulmonary disease

Broadening the reach and
impact of precision medicine
to more people with cancer

Precision therapeutics
for genetically defined
diseases

Harnessing the immune system
to defeat cancer with
tumor-selective immunotherapies

Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)

Next generation ocular gene
therapies for vision restoration
and vision preservation

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Leading the
next frontier in
RNA therapeutics

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Reprogramming RNA processing
to address underlying
drivers of disease

Novel therapeutics
for severe
respiratory diseases

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Rapidly developing new
cancer treatments for
people of all ages

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Engineered
B cells
as medicines

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

New class of
regulated cell and
gene therapies

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020

Discovering new medicines
for severe
neurodegenerative diseases

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

Harnessing the power of microglia
to transform treatments for
neurodegenerative diseases

Precision therapeutics for
genetically-defined dry AMD
(NASDAQ: GMTX) Jan 2021

Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders